1887

Abstract

Three clinical strains, KpARG74, KpARG220 and KpARG185, isolated from a hospital in Algeria, carried the novel β-lactamases SHV-98, SHV-99 and SHV-100, respectively, and co-expressed TEM-1 and either CTX-M-3 or CTX-M-15. In contrast, transformed cells possessing the genes for these novel β-lactamases, i.e. EcDH5α-SHV-98, EcDH5α-SHV-99 and EcDH5α-SHV-100, respectively, carried unique sequence features of gene variants, enabling oxyimino-cephalosporin susceptibility and confirming that none of the transformants exhibited extended-spectrum β-lactamase (ESBL) properties. SHV-100 is apparently functional, despite differing from the SHV-1 sequence by duplication of 13 amino acids. The SHV-99 enzyme differed from the parental SHV-1 by the amino acid substitution Asp104→Gly, which is an important position in the development of the ESBL phenotype in TEM β-lactamases. This is the first time, to our knowledge, that this mutation has been reported in clinically occurring isolates. Thus, kinetic characterization of the SHV-99 enzyme was performed. The SHV-99 enzyme showed higher affinity ( of 196 µM), catalytic activity ( of 0.5 s) and catalytic efficiency ( / of 0.003 µM s) than SHV-1 β-lactamase against aztreonam. These results showed that the neutral glycine at residue 104 increased the affinity of the enzyme to aztreonam, but was unable to develop the ESBL phenotype in SHV enzymes. As the emergence of new threatening combinations of resistance determinants among nosocomial pathogens is further possible, this study has highlighted the need to reverse the spread of initial mutations.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.030577-0
2011-07-01
2024-03-29
Loading full text...

Full text loading...

/deliver/fulltext/jmm/60/7/983.html?itemId=/content/journal/jmm/10.1099/jmm.0.030577-0&mimeType=html&fmt=ahah

References

  1. Ambler R. P., Coulson A. F., Frère J. M., Ghuysen J. M., Joris B., Forsman M., Levesque R. C., Tiraby G., Waley S. G. 1991; A standard numbering scheme for the class A β-lactamases. Biochem J 276:269–270[PubMed]
    [Google Scholar]
  2. Babini G. S., Livermore D. M. 2000; Are SHV β-lactamases universal in Klebsiella pneumoniae?. Antimicrob Agents Chemother 44:2230 [View Article][PubMed]
    [Google Scholar]
  3. Bethel C. R., Hujer A. M., Hujer K. M., Thomson J. M., Ruszczycky M. W., Anderson V. E., Pusztai-Carey M., Taracila M., Helfand M. S., Bonomo R. A. 2006; Role of Asp104 in the SHV β-lactamase. Antimicrob Agents Chemother 50:4124–4131 [View Article][PubMed]
    [Google Scholar]
  4. Bonnet R., Cavallo J. D., Chardon H., Chidiac C., Courvalin P., Dabernat H., Drugeon H., Dubreuil L.,, Guery B., other authors. 2010; Comité de l'antibiogramme de la Société Française de Microbiologie; Recommandations 2010. 26–29 [View Article][PubMed]
    [Google Scholar]
  5. Bush K., Jacoby G. A. 2010; Updated functional classification of β-lactamases. Antimicrob Agents Chemother 54:969–976 [View Article][PubMed]
    [Google Scholar]
  6. Caniça M. M., Barthélémy M., Gilly L., Labia R., Krishnamoorthy R., Paul G. 1997; Properties of IRT-14 (TEM-45), a newly characterized mutant of TEM-type β-lactamases. Antimicrob Agents Chemother 41:374–378[PubMed]
    [Google Scholar]
  7. Guo F., Huynh J., Dmitrienko G. I., Viswanatha T., Clarke A. J. 1999; The role of the non-conserved residue at position 104 of class A β-lactamases in susceptibility to mechanism-based inhibitors. Biochim Biophys Acta 1431:132–147 [View Article][PubMed]
    [Google Scholar]
  8. Hammond D. S., Harris T., Bell J., Turnidge J., Giffard P. M. 2008; Selection of SHV extended-spectrum-β-lactamase-dependent cefotaxime and ceftazidime resistance in Klebsiella pneumoniae requires a plasmid-borne bla SHV gene. Antimicrob Agents Chemother 52:441–445 [View Article][PubMed]
    [Google Scholar]
  9. Knox J. R. 1995; Extended-spectrum and inhibitor-resistant TEM-type beta-lactamases: mutations, specificity, and three-dimensional structure. Antimicrob Agents Chemother 39:2593–2601[PubMed] [CrossRef]
    [Google Scholar]
  10. Kuzin A. P., Nukaga M., Nukaga Y., Hujer A. M., Bonomo R. A., Knox J. R. 1999; Structure of the SHV-1 β-lactamase. Biochemistry 38:5720–5727 [View Article][PubMed]
    [Google Scholar]
  11. Labia R., Andrillon J., Le Goffic F. 1973; Computerized microacidimetric determination of β lactamase Michaelis–Menten constants. FEBS Lett 33:42–44 [View Article][PubMed]
    [Google Scholar]
  12. Mendonça N., Leitão J., Manageiro V., Ferreira E. the Antimicrobial Resistance Surveillance Program in Portugal Caniça M. 2007; Spread of extended-spectrum beta-lactamase CTX-M-producing Escherichia coli clinical isolates in community and nosocomial environments in Portugal. Antimicrob Agents Chemother 51:1946–1955 [View Article][PubMed]
    [Google Scholar]
  13. Mendonça N., Manageiro V., Robin F., Salgado M. J., Ferreira E., Caniça M., Bonnet R. 2008; The Lys234Arg substitution in the enzyme SHV-72 is a determinant for resistance to clavulanic acid inhibition. Antimicrob Agents Chemother 52:1806–1811 [View Article][PubMed]
    [Google Scholar]
  14. Messai Y., Iabadene H., Benhassine T., Alouache S., Tazir M., Gautier V., Arlet G., Bakour R. 2008; Prevalence and characterization of extended-spectrum β-lactamases in Klebsiella pneumoniae in Algiers hospitals (Algeria). Pathol Biol (Paris) 56:319–325[PubMed] [CrossRef]
    [Google Scholar]
  15. Paterson D. L., Bonomo R. A. 2005; Extended-spectrum β-lactamases: a clinical update. Clin Microbiol Rev 18:657–686 [View Article][PubMed]
    [Google Scholar]
  16. Petit A., Maveyraud L., Lenfant F., Samama J. P., Labia R., Masson J. M. 1995; Multiple substitutions at position 104 of β-lactamase TEM-1: assessing the role of this residue in substrate specificity. Biochem J 305:33–40[PubMed]
    [Google Scholar]
  17. Ramdani-Bouguessa N., Mendonça N., Leitão J., Ferreira E., Tazir M., Caniça M. 2006; CTX-M-3 and CTX-M-15 extended-spectrum β-lactamases in isolates of Escherichia coli from a hospital in Algiers, Algeria. J Clin Microbiol 44:4584–4586 [View Article][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.030577-0
Loading
/content/journal/jmm/10.1099/jmm.0.030577-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error